MB and chronic kidney disease: Future studies should validate dynamic FIB4 trajectories across diverse ethnic populations and CKD stages, while developing CKD-specific modified algorithms (e.g., incorporating myoglobin or inflammatory markers) to enhance specificity in non-hepatic conditions.